|
|
|
|
| LEADER |
01753 am a22002773u 4500 |
| 001 |
98866 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Graf, Nora
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Graf, Nora
|e contributor
|
| 100 |
1 |
0 |
|a Mokhtari, Tara E.
|e contributor
|
| 100 |
1 |
0 |
|a Papayannopoulos, Ioannis A.
|e contributor
|
| 100 |
1 |
0 |
|a Lippard, Stephen J.
|e contributor
|
| 700 |
1 |
0 |
|a Mokhtari, Tara E.
|e author
|
| 700 |
1 |
0 |
|a Papayannopoulos, Ioannis A.
|e author
|
| 700 |
1 |
0 |
|a Lippard, Stephen J.
|e author
|
| 245 |
0 |
0 |
|a Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells
|
| 260 |
|
|
|b Elsevier,
|c 2015-09-22T17:34:07Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/98866
|
| 520 |
|
|
|a Cisplatin is one of the most widely used anticancer drugs. Its side effects, however, have motivated researchers to search for equally effective analogs that are better tolerated. Selectively targeting cancer tissue is one promising strategy. For this purpose, a platinum(IV) complex was conjugated to the cancer-targeting peptide chlorotoxin (CTX, TM601) in order to deliver cisplatin selectively to cancer cells. The 1:1 Pt-CTX conjugate was characterized by mass spectrometry and gel electrophoresis. Like most platinum(IV) derivatives, the cytotoxicity of the conjugate was lower in cell culture than that of cisplatin, but greater than those of its Pt(IV) precursor and CTX in several cancer cell lines.
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (Grant CA034992)
|
| 520 |
|
|
|a German Academic Exchange Service (Fellowship)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Journal of Inorganic Biochemistry
|
